Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Impact of Delaying the Addition of Anti-EGFR in First Line of RAS Wild-Type Metastatic Colorectal Cancer: A Propensity-Weighted Pooled Data Analysis

LJ. Palmieri, T. Buchler, A. Meyer, V. Veskrnova, O. Fiala, P. Brabec, J. Baranova, R. Coriat

. 2022 ; 14 (6) : . [pub] 20220310

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22009806

The first-line therapy of patients with RAS wild-type (WT) non-resectable metastatic colorectal cancer (mCRC) is usually 5-fluorouracil-based chemotherapy with either bevacizumab or an anti-epidermal growth factor receptor (EGFR). The addition of anti-EGFR antibodies is commonly delayed in clinical practice because of late RAS testing results. Our objective was to evaluate the impact on overall survival (OS) of a delayed anti-EGFR introduction strategy. This study pooled the data of two large retrospective studies. Patients with RAS WT non-resectable mCRC, treated in first line by a doublet chemotherapy with an anti-EGFR introduced with a delay of 2 to 4 cycles, were compared to an anti-EGFR and to an anti-VEGF that was introduced immediately. Patients numbering 305 in the delayed anti-EGFR group, 401 in the immediate anti-EGFR group, and 129 in the immediate anti-VEGF group were analyzed. After propensity scoring, there was no difference between the characteristics of the three groups. Median OS was 28.6 months (95% CI: 23.5-34.1) in the immediate anti-EGFR group, 35.1 (95% CI: 29.9-43.5) in the delayed anti-EGFR group, and 32.4 (95% CI: 25.4-44.8) in the immediate anti-VEGF group. There was no significant difference concerning median OS (p = 0.24) or progression-free survival (p = 0.56). This study suggests that delaying the introduction of an anti-EGFR has no deleterious impact on survival compared to the immediate introduction of an anti-VEGF or of an anti-EGFR.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22009806
003      
CZ-PrNML
005      
20220425131556.0
007      
ta
008      
220420s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cancers14061410 $2 doi
035    __
$a (PubMed)35326562
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Palmieri, Lola-Jade $u Gastroenterology and Digestive Oncology Department, Cochin Hospital, AP-HP, 27 rue du Faubourg Saint Jacques, 75014 Paris, France $u Faculté de Médecine Paris Centre, Université de Paris, 75006 Paris, France
245    10
$a Impact of Delaying the Addition of Anti-EGFR in First Line of RAS Wild-Type Metastatic Colorectal Cancer: A Propensity-Weighted Pooled Data Analysis / $c LJ. Palmieri, T. Buchler, A. Meyer, V. Veskrnova, O. Fiala, P. Brabec, J. Baranova, R. Coriat
520    9_
$a The first-line therapy of patients with RAS wild-type (WT) non-resectable metastatic colorectal cancer (mCRC) is usually 5-fluorouracil-based chemotherapy with either bevacizumab or an anti-epidermal growth factor receptor (EGFR). The addition of anti-EGFR antibodies is commonly delayed in clinical practice because of late RAS testing results. Our objective was to evaluate the impact on overall survival (OS) of a delayed anti-EGFR introduction strategy. This study pooled the data of two large retrospective studies. Patients with RAS WT non-resectable mCRC, treated in first line by a doublet chemotherapy with an anti-EGFR introduced with a delay of 2 to 4 cycles, were compared to an anti-EGFR and to an anti-VEGF that was introduced immediately. Patients numbering 305 in the delayed anti-EGFR group, 401 in the immediate anti-EGFR group, and 129 in the immediate anti-VEGF group were analyzed. After propensity scoring, there was no difference between the characteristics of the three groups. Median OS was 28.6 months (95% CI: 23.5-34.1) in the immediate anti-EGFR group, 35.1 (95% CI: 29.9-43.5) in the delayed anti-EGFR group, and 32.4 (95% CI: 25.4-44.8) in the immediate anti-VEGF group. There was no significant difference concerning median OS (p = 0.24) or progression-free survival (p = 0.56). This study suggests that delaying the introduction of an anti-EGFR has no deleterious impact on survival compared to the immediate introduction of an anti-VEGF or of an anti-EGFR.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Buchler, Tomas $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Videnska 800, 14059 Prague, Czech Republic $1 https://orcid.org/000000016667994X $7 xx0096851
700    1_
$a Meyer, Antoine $u Hôpital Bicêtre, AP-HP, 78 rue du General Leclerc, 94043 Le Kremlin Bicêtre, France $u Faculté de Médecine, Université Paris Saclay, 94043 Le Kremlin Bicêtre, France $1 https://orcid.org/0000000311569289
700    1_
$a Veskrnova, Veronika $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Videnska 800, 14059 Prague, Czech Republic
700    1_
$a Fiala, Ondrej $u Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, alej Svobody 80, 32300 Pilsen, Czech Republic $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, 32300 Pilsen, Czech Republic $1 https://orcid.org/0000000240967385
700    1_
$a Brabec, Petr $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Netroufalky 5, 62500 Brno, Czech Republic
700    1_
$a Baranova, Jana $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Netroufalky 5, 62500 Brno, Czech Republic
700    1_
$a Coriat, Romain $u Gastroenterology and Digestive Oncology Department, Cochin Hospital, AP-HP, 27 rue du Faubourg Saint Jacques, 75014 Paris, France $u Faculté de Médecine Paris Centre, Université de Paris, 75006 Paris, France $1 https://orcid.org/0000000344208340
773    0_
$w MED00173178 $t Cancers $x 2072-6694 $g Roč. 14, č. 6 (2022)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35326562 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20220420 $b ABA008
991    __
$a 20220425131554 $b ABA008
999    __
$a ind $b bmc $g 1784402 $s 1161004
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 14 $c 6 $e 20220310 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
LZP    __
$a Pubmed-20220420

Najít záznam

Citační ukazatele

Možnosti archivace